Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676425 | 1.00 | TTR (1.00) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL5003674 | 0.80 | TTR (0.67) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL14128530 | 0.80 | TTR (0.67) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL720795 | 0.78 | LCK (1.00) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL720794 | 0.78 | LCK (1.00) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL28285006 | 0.78 | TTR (0.63) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL23754269 | 0.77 | LCK (1.00) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL1425963 | 0.77 | TTR (0.63) | TTRPTGS1MAPTALOX5MAOB | |
| SCHEMBL30194225 | 0.77 | LCK (1.00) | TTRLCKPTGS1KDM4EMEN1 | |
| SCHEMBL23754267 | 0.77 | LCK (1.00) | TTRLCKPTGS1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514929-B2 | Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| CN-116270564-A | Application of 4,3',5' -trihydroxy resveratrol compound in preparation of coronavirus 3CL protease inhibitor | 陕西科技大学 | 2023-06-23 | — | — | CN | claimed |
| US-20200030457-A1 | DEFORMABLE NANO-SCALE VEHICLES (DNVS) FOR TRANS-BLOOD BRAIN BARRIER, TRANS-MUCOSAL, AND TRANSDERMAL DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | claimed |
| CN-110662532-A | Deformable Nanoscale Vehicles (DNVS) for cross-blood brain barrier, transmucosal and transdermal drug delivery | 加利福尼亚大学董事会 | 2020-01-07 | — | — | CN | claimed |
| US-20100204339-A1 | Orally Bioavailable Stilbenoids- Compositions and Therapeutic Applications Thereof | SAMI LABS LTD (IN) | 2010-08-12 | — | — | US | claimed |
| US-12514929-B2 | Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | disclosed |
| CN-116270564-B | Application of 4,3',5' -trihydroxy resveratrol compound in preparation of coronavirus 3CL protease inhibitor | 陕西科技大学 | 2025-07-18 | — | — | CN | disclosed |
| CN-118384138-A | Application of Gnetol and its derivatives in preparing protein phosphatase PPM1B inhibitor and antiaging medicine | 山东大学 | 2024-07-26 | — | — | CN | disclosed |
| CN-116270564-A | Application of 4,3',5' -trihydroxy resveratrol compound in preparation of coronavirus 3CL protease inhibitor | 陕西科技大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-116270564-A | Application of 4,3',5' -trihydroxy resveratrol compound in preparation of coronavirus 3CL protease inhibitor | 陕西科技大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20200030457-A1 | DEFORMABLE NANO-SCALE VEHICLES (DNVS) FOR TRANS-BLOOD BRAIN BARRIER, TRANS-MUCOSAL, AND TRANSDERMAL DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | disclosed |
| CN-110662532-A | Deformable Nanoscale Vehicles (DNVS) for cross-blood brain barrier, transmucosal and transdermal drug delivery | 加利福尼亚大学董事会 | 2020-01-07 | — | — | CN | disclosed |
| US-20120207809-A1 | Method and system for effecting changes in pigmented tissue | MOAZED KAMBIZ THOMAS (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120076848-A1 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE | MOAZED KAMBIZ THOMAS (US) | 2012-03-29 | — | — | US | disclosed |
| US-20110280909-A1 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE | MOAZED KAMBIZ THOMAS (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011011065-A1 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE | MOAZED KAMBIZ THOMAS (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100204340-A1 | ORALLY BIOAVAILABLE STILBENOIDS- COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF | SAMI LABS LIMITED (IN) | 2010-08-12 | — | — | US | disclosed |
| US-20100204340-A1 | ORALLY BIOAVAILABLE STILBENOIDS- COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF | SAMI LABS LIMITED (IN) | 2010-08-12 | — | — | US | disclosed |
| US-20100204339-A1 | Orally Bioavailable Stilbenoids- Compositions and Therapeutic Applications Thereof | SAMI LABS LTD (IN) | 2010-08-12 | — | — | US | disclosed |
| WO-2010087983-A1 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE | MOAZED KAMBIZ THOMAS (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204340-A1 | ORALLY BIOAVAILABLE STILBENOIDS- COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF | SIRT1, SIRT3, LRBA | TTR 3502/4885LCK 4518/4885PTGS1 1943/4885 |
| US-20100204339-A1 | Orally Bioavailable Stilbenoids- Compositions and Therapeutic Applications Thereof | SIRT1, SIRT2, SIRT3 | TTR 4522/4885LCK 4613/4885PTGS1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.